⌕
Tarsus Pharmaceuticals · TARS · Nasdaq
Tenet 34 · Weak
Compare
$78.20−0.61%At closeTenet 34 · Weak
$78.20−0.48 (−0.61%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Tarsus Pharmaceuticals (TARS) Institutional Ownership

13F filers reported holding 8.1% of Tarsus Pharmaceuticals (TARS) shares as of Sep 30, 2026, across 92 filers.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice
Held by 13F filers
8.1%
Sep 30, 2026
13F filers
92
quarter ended Sep 30, 2026
13F value
$312.7M
4.0M shares
Quarter's fund flow
Mild accumulation
13 new · 12 closed

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (13 new · 38 increased · 23 reduced · 12 closed · 6 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
Basis: shares reported by 92 13F filers for Sep 30, 2026, over shares outstanding implied from the current quote, measured 49 days apart. It measures the ownership we have filings for, not total institutional ownership, and it moves with the share count between filings.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Sep 4, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale5,387$85.00↗
Sep 4, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale5,386$90.00↗
Sep 4, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale1,590$85.00↗
Sep 4, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale1,590$90.00↗
Sep 4, 2026Azamian Bobak R.President/CEO and Board ChairDisposed · Open-market sale7,100$90.27↗
Sep 4, 2026Azamian Bobak R.President/CEO and Board ChairDisposed · Open-market sale2,900$91.27↗
Sep 4, 2026Neervannan SeshadriChief Operating OfficerDisposed · Open-market sale4,564$85.00↗
Sep 2, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale5,387$80.00↗
Sep 2, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale1,590$80.00↗
Sep 2, 2026Azamian Bobak R.President/CEO and Board ChairDisposed · Open-market sale10,000$80.06↗
Sep 1, 2026Lin Elizabeth YeuChief Medical OfficerDisposed · Open-market sale4,601$73.86↗
Jun 25, 2026Goodrich KatherinedirectorAcquired · Grant / award3,837Stock Option (right to buy)—↗
Jun 25, 2026Goodrich KatherinedirectorAcquired · Grant / award2,417Restricted Stock Units—↗
Jun 25, 2026Goldberg Andrew D.directorAcquired · Grant / award3,837Stock Option (right to buy)—↗
Jun 25, 2026Goldberg Andrew D.directorAcquired · Grant / award2,417Restricted Stock Units—↗
Jun 25, 2026Morrison Scott WdirectorAcquired · Grant / award3,837Stock Option (right to buy)—↗
Jun 25, 2026Morrison Scott WdirectorAcquired · Grant / award2,417Restricted Stock Units—↗
Jun 25, 2026CHAUDHURI BHASKARdirectorAcquired · Grant / award3,837Stock Option (right to buy)—↗
Jun 25, 2026CHAUDHURI BHASKARdirectorAcquired · Grant / award2,417Restricted Stock Units—↗
Jun 25, 2026LINK WILLIAM J PHDdirectorAcquired · Grant / award3,837Stock Option (right to buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How much of Tarsus Pharmaceuticals do institutions hold?

13F filers reported holding 8.1% of Tarsus Pharmaceuticals' shares as of Sep 30, 2026, across 92 filers.

How many 13F filers hold Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals was held by 92 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.